NTLA - インテリア・セラピュ―ティクス （Intellia Therapeutics Inc.）

https://www.investing.com/news/pro/intellia-therapeutics-inc-receives-investment-bank-analyst-rating-update-3073986

Intellia Therapeutics, Inc. (NASDAQ: NTLA ) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002 first-in-human studies in the coming months. NTLA reported first-quarter FY23 collaboration revenue of $12.61 million, up 12% year over year, beating the analyst consensus of $11.83 million . The … Full story available on Benzinga.com

Intellia Therapeutics (NTLA) added ~13% on Thursday after the gene-editing company reported its Q1 2023 financials alongside updates from its pipeline. Read more here.

Intellia Therapeutics, Inc. (NASDAQ:NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ETCompany ParticipantsIan Karp - Senior Vice President, Investor Relations and…

The following slide deck was published by Intellia Therapeutics, Inc.

As of Tuesday, Intellia Therapeutics Inc.’s (NASDAQ:NTLA) stock closed at $40.03, down from $40.08 the previous day. While Intellia Therapeutics Inc. has underperformed by -0.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NTLA fell by -38.46%, with highs and lows ranging from $78.58 to $32.44, […]

Aside from artificial intelligence (AI) and cryptocurrencies, a longtime hot stock on Wall Street revolves around gene editing research and develop…

Intellia is well-positioned to capitalize on the growing demand for gene editing therapies. Click here to learn more about what makes NTLA stock a Buy.

Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation. Cathie Wood’s portfolio can be found here and includes hundreds of holdings primarily in tech. Wood’s ARK Investment Management includes several actively managed ETFs that focus on high-growth companies in fields such as genomics, robotics, and fintech. ARK’s most popular funds include the ARK Innovation ETF (NYSEARCA: ARKK ), ARK Next Generation Internet ETF (NYSEARCA: ARKW ), and ARK Genomic Revolution ETF (BATS: ARKG ). Of course, any investor seeking to invest in Cathie Wood stocks could simply establish a position in any of those ETFs. That would be a reasonable method for following her investment methods. However, this list consists of individual stock picks all found within ARK’s respective ETFs. NVDA Nvidia $234.27 TSLA Tesla $189.67 NTLA Intellia Therapeutics $40.51 ADYEY Adyen $14.43 CAT Caterpillar $248.26 CRSP CRISPR $48.18 MGA Magna International $55.59 Cathie Wood Stocks: Nvidia (NVDA) Source: Michael Vi / Shutterstock.com Most investors know Nvidia (NASDAQ: NVDA ) as a leading semiconductor company that designs and manufactures advanced graphics processing units for gaming, data centers, and artificial intelligence.

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping up 10%. However, prospective investors should also recognize certain risk factors. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats , represents “…the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology,” according to the Broad institute. Scientists note that this innovation underlies a faster, cheaper and more accurate process of DNA editing than previous techniques. Specifically for NTLA stock, the FDA’s go-ahead to Intellia represents the first domestic test of an in-vivo gene-editing drug. According to Investor’s Business Daily , “With this approach, the genetic edit takes place inside the body.

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ: NTLA ) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping up 10%. However, prospective investors should also recognize certain risk factors. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats , represents “…the hallmark of a bacterial defense system that forms the basis for CRISPR-Cas9 genome editing technology,” according to the Broad institute. Scientists note that this innovation underlies a faster, cheaper and more accurate process of DNA editing than previous techniques. Specifically for NTLA stock, the FDA’s go-ahead to Intellia represents the first domestic test of an in-vivo gene-editing drug. According to Investor’s Business Daily , “With this approach, the genetic edit takes place inside the body.

Intellia Therapeutics landed a historic regulatory nod from the FDA.

OKTA and KR climbed on earnings news. PLUG fell after its quarterly update. NTLA rose after receiving FDA clearance for a clinical trial.

The FDA cleared Intellia to begin testing its CRISPR gene-editing technology in people on Thursday, leading NTLA stock to jump.

Shares of Intellia Therapeutics Inc. NTLA rallied about 10% in premarket trading on Thursday after the company said the Food and Drug Administration will allow its experimental CRISPR therapy to move into the Phase 2 part of the Phase 1/2 clinical trial. The single-dose therapy is being assessed as a treatment for hereditary angioedema, a rare disorder that causes severe swelling. Intellia plans to share data from the Phase 1 part of the study later this year. The company’s stock is up 16.8% so far this year, while the broader S&P 500 SPX has gained 3.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.